Prion (PrPC) expression in ovine uteroplacental tissues increases after estrogen treatment of ovariectomized ewes and during early pregnancy

Mary Lynn Johnson1,2, Anna T Grazul-Bilska1,2, Lawrence P Reynolds1,2 and Dale A Redmer1,2

1Department of Animal Sciences and 2Center for Nutrition and Pregnancy, North Dakota State University, Fargo, North Dakota 58108, USA

Correspondence should be addressed to M L Johnson; Email: mary.lynn.johnson@ndsu.edu

Abstract

Scrapie in sheep is spread laterally by placental transmission of an infectious misfolded form (PrPSc) of a normal prion protein (PrPC) used as a template in PrPSc formation. We hypothesized that PrPC would be expressed in uterine and placental tissues and estradiol-17β (E2) would affect uterine PrPC expression. PrPC expression was evaluated in the uterus of long-term ovariectomized (OVX) ewes treated with an E2 implant for 2–24 h and in uteroplacental tissues from day 20 to day 30 of pregnancy. Expression of PrPC mRNA and PrPC protein increased in the uterus after E2 treatment of OVX ewes. In the maternal placenta, expression of PrPC mRNA and PrPC protein were unchanged, but in the fetal membranes (FM) PrPC mRNA and PrPC protein expression increased from day 20 to day 28. In the nonpregnant uterus, PrPC protein was immunolocalized at apical borders of the surface epithelium, in outer smooth muscle layers of large blood vessels, and in scattered stromal cells of the deep intercaruncular areas of the uterus. In the maternal placenta, PrPC protein was immunolocalized in the cytoplasm of flattened luminal epithelial cells apposed to the FM, whereas in the FM PrPC protein was in trophoblast cells and was also in several tissues of the developing embryo during early pregnancy. These data linking estrogen stimulation to increases in PrPC expression in uteroplacental tissues suggest that PrPC has a specific function during the estrous cycle and early pregnancy. Future studies should determine whether or not estrogen influences PrPC expression in other tissues, such as the nervous system and brain.

Reproduction (2014) 148 1–10

Introduction

Scrapie is a fatal and incurable neurological disease in sheep and belongs to a family of prion diseases known as transmissible spongiform encephalopathies (TSEs). Other well-known members of the prion disease family include bovine spongiform encephalopathy (BSE), variant Creutzfeldt–Jakob disease (the disease associated with BSE transmission to humans), and chronic wasting disease of Cervidae (deer, elk, moose, and related species). Scrapie is believed to be transmitted laterally (from sheep to sheep) via ingestion of the infected placenta at lambing. However, the mechanisms of scrapie transmission are not fully understood nor are the cells responsible for transfer and conversion of the normal prion protein (PrPC) to the abnormal infectious protein (PrPSc) positively identified. Nevertheless, PrPC must be present as it acts as a template for the conversion to PrPSc (Brandner et al. 1996, Colby & Prusiner 2011). PrPC has previously been found in numerous sheep reproductive tissues and shown to increase during pregnancy in caruncular (CAR) endometrium (Tuo et al. 2001). PrPC has also been detected in sheep blood (Halliday et al. 2005).

The precise physiological role of PrPC is presently unknown. However, a few of the functions that have been proposed for PrPC include neuroprotection, protection against oxidative stress, promotion of cell signaling cascades, involvement in cell adhesion, a role in cancer processes involving either inhibition or promotion of apoptosis, and a role in progression of Alzheimer’s disease (AD; reviewed in Nicholas et al. (2009) and Mehrpour & Codogno (2010)). Additionally, Alfaidy et al. (2013) have reported that PrPC affects key angiogenic processes necessary for establishment of fetomaternal circulation and subsequent growth of the placenta through modulation of copper (Cu) homeostasis in humans. Either overexpression or no expression of PrPC in genetically engineered mice was shown to cause intrauterine growth retardation (IUGR), which is a major complication of pregnancy (Alfaidy et al. 2013). Thus, it seems apparent that PrPC expression plays a role in early placental development, but quantification of PrPC...
expression during early pregnancy and determination of which cells express PrPC has not been reported.

Estradiol-17β (E2) is a known modulator of the cyclic patterns of uterine growth and tissue remodeling that occurs during the estrous cycle (Reynolds & Redmer 2001, Reynolds et al. 2002). The uterotropic effects of E2 during early pregnancy promote increased blood flow to support embryonic development and placentation (Magness et al. 1998, Reynolds et al. 1998a, b, 2002, 2004, 2010). Besides promoting blood flow, E2 has profound effects on various factors that promote angiogenesis and affect uteroplacental cell proliferation, growth, and differentiation (Reynolds & Redmer 1992, 1995, 2001, Johnson et al. 1997, 2006, Reynolds et al. 1998a, b, 2010). Similarly, based on the interaction of PrPC with proteins known to be active in cell signaling pathways, a role for PrPC in promoting cell survival, differentiation, and prevention of apoptosis has been proposed (Nicholas et al. 2009, Mehrpour & Codogno 2010, Rigter et al. 2010). However, whether or not E2 might promote increased expression of PrPC during growth of uterine tissues has not been evaluated.

We have developed a well-tested ovariectomized (OVX) ewe model for examining the effects of E2 on growth and vascularization of endometrial tissues (Johnson et al. 1997, 2006, Reynolds et al. 1998a, b), and we have established another model for studying placental development during early pregnancy (Reynolds & Redmer 1992, 1995, Grazul-Bilska et al. 2010, 2011). These models are used in this study to examine whether or not PrPC expression is influenced by E2 and is developmentally regulated during early pregnancy. Our hypothesis was that expression of PrPC mRNA and/or PrPC protein would increase in a cell-specific manner in the uterus after E2 treatment in long-term OVX ewes and would increase in uteroplacental tissues and the developing embryo from day 20 to day 30 after mating during early pregnancy in sheep. Our objectives were: i) to quantify the effects of E2 treatment on uterine PrPC mRNA and PrPC protein expression in OVX ewes, ii) to quantify levels of uteroplacental PrPC mRNA and PrPC protein expression from day 20 to day 30 of early pregnancy, and iii) to localize PrPC protein in specific endometrial cells after E2 treatment and in placental and embryonic tissues during early pregnancy.

**Materials and methods**

**Animals and treatments**

For both experiments, all animal use and care procedures were approved by the Institutional Animal Care and Use Committee at NDSU.

**Experiment 1**

To examine the effects of E2 treatment on PrPC mRNA and PrPC protein expression, we used an OVX ewe model that we have previously validated and described in several studies (Johnson et al. 1997, 2006, Reynolds et al. 1998a, b). Briefly, on days 10–12 after estrus, ewes (n=32) of mixed breed were OVX and allowed to recover for at least 30 days before steroid treatment was initiated. Two silicone elastomer implants containing 100 mg of E2 were inserted subcutaneously into each ewe, and the uterus was collected at 0 h (controls), or at 2, 4, 8, 16, or 24 h after receiving the E2 implant (n=4–6 per time point; Johnson et al. 1997, Reynolds et al. 1998a, b). After weighing the intact uterus, CAR and intercaruncular (ICAR) tissues were dissected from the endometrium; one portion was snap–frozen and stored at −70 °C for isolation of mRNA and protein, and the second portion was fixed in formalin for immunolocalization of PrPC protein. In the sheep endometrium, the CAR tissue contains numerous blood vessels, but no glands, whereas ICAR tissue contains secretory glands and blood vessels. Therefore, these two areas of the endometrium are not only morphologically different, but also functionally different tissues, which is why we collected them separately.

**Experiment 2**

The animal model for this experiment has been described in detail by Grazul-Bilska et al. (2010, 2011). Briefly, mature, nonpregnant (NP), western range-type ewes (n=38) of mixed breed (predominantly Targhee × Rambouillet) were checked twice daily for behavioral estrus using vasectomized rams and were bred at estrus (day 0=d day of estrus) by intact rams. Maternal placenta (CAR), and fetal membranes (FM) or chorioallantois of the fetal placenta, and developing embryos (n=1–3/ewe) were collected from ewes on days 20, 22, 24, 26, 28, and 30 of pregnancy (n=5/day), and CAR tissue was collected from NP ewes (n=5) on day 10 of the estrous cycle (controls). Similar to Experiment 1, a portion of CAR tissue, and FM were snap–frozen and stored at −70 °C for isolation of mRNA and protein, and developing embryos (n=1/ewe) as well as a cross section of uterus containing placental tissue were fixed in formalin for immunolocalization of PrPC protein.

In both experiments, quantitative real-time RT-PCR (qRT-PCR) was used for analysis of PrPC mRNA expression, immunohistochemistry was used for localization of PrPC protein to specific cell/tissue compartments, and western analysis was used for quantification of PrPC protein expression.

**Quantitative real-time RT-PCR analysis of PrPC mRNA expression**

The procedures for determining the expression of mRNA for PrPC in ovine E2-treated endometrium, uteroplacenta, and embryo by qRT-PCR were reported previously (Johnson et al. 2006, Grazul-Bilska et al. 2010). Briefly, snap–frozen tissues were homogenized in Tri-Reagent (Molecular Research, Inc., Cincinnati, OH, USA) according to the manufacturer’s specifications. The quality and quantity of total RNA were determined by capillary electrophoresis using the Agilent 2100 Bioanalyzer (Agilent Technologies, Wilmington, DE, USA). Quantitative real-time RT-PCR reagents, TaqMan probes, and primers were purchased from and used as recommended by Applied Biosystems. For each sample, 30 ng of total RNA were
reverse transcribed with random hexamers in triplicate 20 μl reactions. PrPC sequence-specific TaqMan probe and primer sets were designed from 100% homologous regions in the 5’ end of the sheep prion gene (forward, 5’-TTTTTGCCATG-TGGAGTGA-3’; reverse, 5’-CCATCTCAGCGAGTCTT-3’; and 5’-TGGAGTGA-3’; accession numbers JX187517–J187539) using the Primer Express Software from Applied Biosystems (Johnson et al. 2006, Evoniuk et al. 2007). The sequences were validated using NCBI BLAST separately on the primers, probe, and entire amplicon.

The ABI PRISM 7000 was used for detection of sequences amplified in a 12.5-μl reaction volume at 60 °C for 40 cycles (Applied Biosystems) in triplicate wells. Quantification was determined from a relative standard curve of dilutions of the cDNA generated from tRNA pooled from placemones collected on day 130 of pregnancy. To control for variations in the amount of RNA used, individual samples were simultaneously analyzed in a multiplex reaction for concentrations of 18S RNA using the 18S PDAR kit from Applied Biosystems (Johnson et al. 2006, Evoniuk et al. 2007).

**Results**

**Statistical analysis**

Data were analyzed using the general linear models procedure of the Statistical Analysis System (SAS 2008), with time after E2 or day of pregnancy as the main effect and the interaction of time after E2 or day of pregnancy as the main effect and the interaction of time (day) and tissue included in the model. Data for qRT-PCR detection of PrPC mRNA and western analysis of PrPC protein in Experiment 1 were converted to fold increase above controls (0 h) which were set at 1, whereas in Experiment 2 the raw data obtained directly from qRT-PCR or densitometry analyses were statistically analyzed. Differences between specific means were determined using post-hoc analysis by the least significance difference test (Kirk 1982).

**Results**

**Experiment 1**

Expression of PrPC mRNA in CAR tissue increased (P<0.01) by ~1.5-fold after 8 h of E2 treatment and then decreased (P<0.02) to half that of controls at 24 h after E2 (Fig. 1). However, in ICAR tissue, PrPC mRNA expression was statistically unchanged from 2 to 24 h after E2 treatment (Fig. 1) even though the pattern of expression was similar to CAR tissue.

PrPC protein, with a size estimated between 30 and 40 kDa was detected by western immunoblot analysis in both CAR and ICAR tissues (shown at top of Fig. 2). PrPC protein expression increased (P<0.02) by approximately two- to threefold in both CAR and ICAR tissues, at 2–24 h after E2 treatment (Fig. 2).

As the patterns of mRNA and protein expression were similar in CAR and ICAR tissues, there was no significant tissue by time interaction for either of them (P>0.1).
Immunolocalization of PrPC protein in the endometrium of E2-treated OVX ewes revealed that PrPC was predominantly found in arterioles and venules of both CAR and ICAR tissues of all samples (Fig. 3). PrPC was not found in uterine glands. The intense staining for PrPC protein seen in blood vessels was present in cells that appeared to be vascular smooth muscle and adventitial cells, but was not found in the endothelial cell layer of these blood vessels. At 16–24 h after E2 treatment, PrPC protein was present sporadically in the outer layers of smooth muscle and adventitia of larger blood vessels, when PrPC protein had disappeared from most of the smaller blood vessels (Fig. 3). PrPC was also found in the myometrium (not shown).

**Experiment 2**

Compared with NP animals, expression of PrPC mRNA in CAR tissue was unchanged across all days of early pregnancy (Fig. 4A). In FM, however, expression of PrPC mRNA increased \( (P<0.05) \) from day 20 to day 28 of pregnancy and then decreased \( (P<0.05) \) on day 30 to the levels present on day 24 (Fig. 4B).

PrPC protein was detected by western immunoblot analysis at a size estimated between 30 and 45 kDa in both CAR tissue and FM in all stages of pregnancy that were evaluated (top of Fig. 5A and B). However, PrPC protein was expressed as a single band in CAR tissue and a doublet in FM. Compared with NP animals, expression of PrPC protein in CAR tissue was unchanged across all days of early pregnancy (Fig. 5A). Expression of PrPC protein in FM (Fig. 5B), however, increased \( (P<0.05) \) from day 20 to day 28 of pregnancy and then decreased \( (P<0.05) \) on day 30. Therefore, in CAR tissue, neither PrPC mRNA (Fig. 4A) nor PrPC protein (Fig. 5A) expression changed, whereas in FM the pattern of change for PrPC mRNA (Fig. 4B) and PrPC protein (Fig. 5B) expression closely paralleled each other. Thus, there was a significant \( (P<0.01) \) tissue by day interaction for PrPC mRNA and PrPC protein expression.

In NP ICAR tissue, PrPC protein was present at the apical borders of the luminal epithelium and that of a few luminal glands (Fig. 6). PrPC protein was also present in the outer smooth muscle and adventitial layers of arterioles and venules and in scattered stromal cells of the deep ICAR tissue of the uterus (Fig. 6).

For CAR tissue, from day 20 to day 30 of pregnancy, PrPC was seen in the cytoplasm of flattened luminal epithelial cells apposed to the FM, whereas in FM, PrPC was localized to mononucleate, binucleate, and multicellular trophoblast cells (Fig. 6).

In embryos, PrPC protein was predominantly present in the mesonephros on days 20–26 of pregnancy but was also found in the spinal cord and midbrain (Fig. 7). By day 26 of pregnancy, PrPC protein was also found in binucleate cells of the fetal liver. By days 28–30, PrPC protein was expressed in fetal mesonephros and in peripheral nerves in areas surrounding the spinal cord and the intestinal tract (Fig. 7).

**Discussion**

To our knowledge, this research presents the first data linking levels of expression of PrPC in the sheep uterus to stimulation by the uterotrophic effects of E2 and to placentation and uterine growth during early pregnancy in sheep. There are few reports of this phenomenon; however, many suggested functions for PrPC (Nicholas et al. 2009, Mehrpour & Codogno 2010, Rigter et al. 2010) are similar to those known to be associated with E2-stimulated processes, such as cell proliferation and prevention of apoptosis (Johnson et al. 1997, Reynolds et al. 1998a,b). Additionally, our data extend our knowledge of which uteroplacental cells are expressing PrPC.
PrPC and how PrPC expression changes during the early stages of pregnancy, a time when some of the most dramatic developmental processes such as implantation and placentation are occurring under the influence of steroids and other factors (Zheng et al. 1996, Reynolds et al. 1998a, b, 2002, 2004, 2010, 2013, Johnson et al. 2006).

We found that E2 up-regulated PrPC mRNA expression in CAR tissue, but not in ICAR tissue, by 8 h after E2 treatment, followed by a decrease at 24 h. At 8 h following E2 expression, we have shown that cell proliferation dramatically increases in association with maximal expression of mRNA for VEGFA (VEGF) and FGF2 (Reynolds et al. 1998a, b). In this study, within 2 h after E2 treatment, PrPC protein expression increased by more than twofold in both the highly vascularized CAR tissue and in the glandular ICAR tissue, a reaction that was maintained through 24 h after E2. The significance of these changes is unclear because the function of PrPC in reproductive tissues is still unknown. Speculation that PrPC functions as a receptor for ligand uptake or transmembrane signaling is based on the fact that PrPC is found on cell surfaces and is recycled through endocytotic pathways, as are numerous other reproductive signaling molecules, including LH, FSH, TGFβ, and IGF (Harris 1999, Forde et al. 2008, Rigter et al. 2010).

Although we cannot explain the discrepancy between mRNA and protein expression in this study, other investigators have reported dynamic regulation of prion protein turnover independent of gene expression or mRNA stability (Choi et al. 2010). Thus, differential regulation of uterine prion protein and mRNA levels seems to be a reasonable speculation and a worthwhile topic of future studies.

Our data demonstrate that E2 treatment not only influenced levels of PrPC protein expression in the NP uterus, but also affected the uterine cells that expressed...
PrPC was mostly present in small and large blood vessels after E2 treatment. This finding is interesting given the role of E2 in promoting vascularization and increased blood flow to the uterus in preparation for uterine growth, implantation, and placentation (Magness et al. 1998, Reynolds et al. 1998a, b, 2002, 2004, 2010). PrPC was mainly present in the muscular and adventitial layers of the blood vessels. This may point to PrPC having a role in cell signaling cascades promoting the vascular development that is stimulated by E2. Alternatively, it has been suggested that PrPC has a protective function that occurs after injury to blood vessels (Zocche Soprana et al. 2011).

Similar to others, we found that PrPC was present in the myometrium of NP and pregnant ewes but was unaffected by E2 treatment (Tanji et al. 1995, Tuo et al. 2001, Thumdee et al. 2007). The role of PrPC in regulation of myometrial function remains to be determined.

PrPC was found in apical areas of luminal epithelial cells and the epithelia of a few luminal glands in NP intact ewes used for controls in the early pregnancy study, but was not found in epithelial cells of the E2-treated OVX ewes. However, PrPC was found in the flattened epithelial cells of the maternal placenta during early pregnancy. These maternal epithelial cells are in close contact with the trophoblast cells of the fetal placenta, where PrPC was also present. PrPC has been found in the apical domain of human intestinal epithelial cells as well (De Keukeleire et al. 2007). Thus, we could speculate that epithelial cells and trophoblast cells might be the site where PrPC is converted to PrPSc in the placenta. In fact, PrPC has been shown to be over-expressed in multinucleate trophoblast cells, which are

**Figure 5** Expression of PrPC protein in caruncle (CAR) tissue (A) and fetal membranes (FM; B) during early pregnancy in ewes. A representative membrane of the western blots is shown on the top of the graph, where the tissues and samples are shown in the same order as they are on the bar graph below. PrPC protein had a molecular weight between 30 and 45 kDa. Note that PrPC protein was expressed as a single band in CAR tissue, but as two protein bands in FM. NS, not significant; \*P means ± s.e.m. with different superscripts differ as indicated on the graph. Values are from densitometry of the western blots. The pattern of change in FM for PrPC mRNA (Fig. 4) and PrPC protein expression closely paralleled each other.

**Figure 6** Representative images of PrPC protein localization (dark staining) in uterine and uteroplacental tissues of nonpregnant (NP; A and B) ewes and pregnant ewes from day 20 to day 30 after mating (C, D, E, and F). Note a lack of positive staining in control (inset in C), where primary antibody was replaced with mouse IgG. Arrows indicate some areas of PrPC-positive (dark) staining; the counterstaining (pink) was with nuclear fast red. L, lumen of uterus; g, uterine gland; En, endometrium; FM, fetal membranes (chorioallantois); myo, myometrium; and *, blood vessels. Note the presence of PrPC protein in NP animals at the apical borders of the luminal epithelia and epithelia of luminal glands (A), larger blood vessels (primarily vascular smooth muscle and adventitia), and in some cells in stromal tissues of endometrium (B). In tissues from pregnancy, PrPC was in luminal epithelia adjacent to the FM (C), in myometrium (D), in luminal epithelial cells of the maternal caruncle (F; arrow), in bi- and multinucleated cells of the placenta (F; arrowheads), and in larger blood vessels and some cells in stromal tissues (E). Size bars = 50 µm.
Figure 7 Representative images of immunolocalization of PrPC protein in a longitudinal section of an embryo on day 20 (A), and fetal tissues from days 20 (B and C), 22 (D), 24 (E), 26 (F), 28 (G), and 30 (H, I, and J) of early pregnancy. Note a lack of positive staining in control (K) where primary antibody was replaced with mouse IgG. Arrows indicate areas of PrPC-positive (dark) staining in contrast to the background (pink) stained with nuclear fast red. sp, spinal cord; pn, peripheral nerves; liv, liver; int, intestine; and me, mesonephros. Note the presence of PrPC in the spinal cord (B, D, and G), peripheral nerves associated with the intestine and other peripheral nerves (E, H, I, and J), liver (F), and mesonephros (C). Size bars = 500 µm on A, 100 µm on B–E and G–K, and 200 µm on F.
the sites where PrPSc accumulates and spreads to uninucleate trophoblast cells (Lacroux et al. 2007).

PrPC mRNA and PrPC protein expression have been shown to be greatest in the first trimester of human placenta growth (Donadio et al. 2007). In that study, expression of PrPC mRNA and PrPC protein were unchanged in the maternal placenta during early pregnancy, but increased linearly until day 28 in the fetal placenta, similar to our observations in the present study. These data suggest a need for further studies of the function(s) of PrPC, especially during the rapid growth and differentiation of the fetal placenta and the developing embryo. For example, under the influence of E₂, the capillary volume of the placenta increases dramatically after day 18 of pregnancy and becomes increasingly more branched in the fetal placenta during later pregnancy resulting in smaller, more numerous capillaries, whereas in the maternal placenta capillary numbers remain about the same but their size increases to accommodate increased blood flow (Borowicz et al. 2007, Reynolds et al. 2010). Others have reported a role for PrPC in Cu homeostasis and regulation of hypoxic stress that may lead to IUGR (Alfaidy et al. 2013). In fact, during hypoxic conditions, PrPC expression is induced by HIF1α, which in turn is activated by Cu (Feng et al. 2009, Jeong et al. 2012). Thus, a role for placental PrPC in placental and fetal development seems likely.

It was noteworthy that PrPC protein presented as two bands in the western analysis of FM, but as only one in CAR tissue and the E₂-treated OVX ewe endometrium. These differences likely reflect the pattern of PrPC glycosylation and also could be related to the length of the PrPC transcript after its activation by proteolytic cleavage. PrPC can exist in three variable forms, as un-, mono-, and di-glycosylated at either of two asparagine residues in its mature length of 208 residues (Cancellotti et al. 2013). Thus, the size of PrPC protein in western blots has been reported as varying from 23 to 44 kDa in sheep reproductive tissues (Horiuchi et al. 1995, Tuo et al. 2001). However, recent reports have suggested that there is a well-conserved hydrophobic core containing a site, commonly referred to as the β-cleavage site, where PrPC is cleaved during normal proteolysis into two fragments, C1 (C-terminal) and N1 (N-terminal) (Yusa et al. 2012). These C1 and N1 fragments were detected in western blots after removal of glycosylation sites (Yusa et al. 2012, Cancellotti et al. 2013). When proteolysis of PrPC is blocked, it apparently becomes neurotropic, suggesting that the normal physiological function of PrPC depends on its cleavage into C1 and N1 (Yusa et al. 2012). Therefore, the two bands for PrPC present in the FM may suggest that PrPC has a specific function in the fetal placenta but not in the maternal placenta. The increase in PrPC expression in the fetal placenta from day 20 to day 28 of pregnancy that we report herein also supports this suggestion, because it corresponds with rapid growth and vascularization of the placenta (Reynolds & Redmer 1992, Gruzel-Bilska et al. 2010, 2011).

Expression of PrPC mRNA and PrPC protein in bovine and ovine fetuses and maternal tissues have been evaluated previously, and the recently reported time- and tissue-specific expression closely resembles the results of our study (Thumdee et al. 2007, Peralta et al. 2012). Early sheep pregnancy (gestation = ~145 days) from day 20 to day 30 closely correlates with the intervals reported for bovine early pregnancy (gestation = ~278 days) from day 27 to day 39 (Peralta et al. 2012). In this study, PrPC was predominantly present in ovine neural tissues of the embryo in early pregnancy, but was also present in liver and mesonephros, as early as day 20 of pregnancy and was expressed in the same cell-specific manner as in cows. On day 26, PrPC expression in the liver was found in scattered uninucleated cells, and these likely were macrophages, similar to the findings in cows (Peralta et al. 2012). The expression of PrPC in neural tissues of the developing embryo suggests that PrPC has a role in neural differentiation (Peralta et al. 2011, 2012). We found PrPC in the spinal cord of day 20 sheep embryos and PrPC expression in peripheral nerves by days 26–30, which was also similar to PrPC expression in cows (Peralta et al. 2012).

As our research has demonstrated that E₂ increased PrPC expression in the uterus, research to evaluate E₂ effects on PrPC expression in the brain should be encouraged. In fact, E₂ has recently been found to prevent PrPSc infection of healthy cells and to enable PrPC maintenance as a treatment for TSE infection (Molloy & McMahon 2014). Interesting comparisons are also being made between onset of AD and actions of PrPC in the brain. The research demonstrates that PrPC may be a receptor for soluble amyloid B (AB) peptide fragments or may serve as an inhibitor of the neurotoxic effects of insoluble AB fragments (Laurén et al. 2009, Nieznanski et al. 2012). Additionally, E₂ has been shown to have neuroprotective effects in postmenopausal women including delay of the onset of AD (Tang et al. 1996, Dublin & Wise 2002, Wise et al. 2009, Barron & Pike 2012). Thus, if PrPC is an important factor in neuroprotection against AD, future studies should continue evaluating how E₂ affects prion expression in the brain and possibly blocks AD.

In summary, we have presented novel data linking E₂ with increases in expression of PrPC in the uterus and have shown that PrPC expression increases in a time-specific manner in the fetal placenta during early pregnancy. Moreover, we have demonstrated localization of PrPC to blood vessels after E₂ treatment, suggesting a role for PrPC in the uterotrophic effects of E₂, including regulation of vascular function and growth. Additionally, we have reported the cell-specific expression of PrPC in epithelia of the uterine endometrium and in trophoblast cells of the FM and suggest that PrPC may be involved in the adhesion of FM to the endometrium in sheep. These sites of robust PrPC...
expression in the uterus and placenta are likely those where conversion to PrPSc occurs and that may provide clues as to how scrapie is spread in sheep during lambing. The novel evidence that E2 increases PrP expression in uterine tissues may lead to future studies focused on whether E2 increases PrP expression in the other tissues, and especially brain and nervous system where PrP may be a key factor in combating AD.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This project was supported by funding from the Animal Disease Research Unit, Animal Research Service, U.S. Department of Agriculture (5348-32000-021-00D), USDA grant (2007-01215) to LP Reynolds and AT Grazul-Bilska, Hatch Project ND1727, and the INBRE program of the National Center for Research Resources, NIH (grant number P20RR016741).

Acknowledgements

The authors acknowledge Dr Katherine I O’Rourke, USDA-ARS, Pullman, WA, for funding and leadership in the PrPc studies at North Dakota State University. They also acknowledge Dr Jerzy Bilski, Dr Pawel Borowicz, Ms Tammi Neville, Mr James D Kirsch, Mr Kim C Kraft, Mr Robert Weigl, Mr Terry Skunberg, and other members of our laboratory and department for their assistance and the efforts of several of our graduate and undergraduate students in this research project: Roza Yunosova, Mahalakshmi Razdan, Anirudh Gautam, and Mathilde Rupin.

References

Alfaidy N, Chauvet S, Donadio-Andrei S, Salomon A, Saoudi Y, Richaud P, Gautam, and Mathilde Rupin. project: Roza Yunosova, Mahalakshmi Razdan, Anirudh
our graduate and undergraduate students in this research department for their assistance and the efforts of several of Mr James D Kirsch, Mr Kim C Kraft, Mr Robert Weigl, Mr Terry
recommends the INBRE program of the National Center for Research Resources, NIH (grant number P20RR016741).

The novel evidence that E2 increases PrP expression in uterine tissues may lead to future studies focused on whether E2 increases PrP expression in the other tissues, and especially brain and nervous system where PrP may be a key factor in combating AD.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This project was supported by funding from the Animal Disease Research Unit, Animal Research Service, U.S. Department of Agriculture (5348-32000-021-00D), USDA grant (2007-01215) to LP Reynolds and AT Grazul-Bilska, Hatch Project ND1727, and the INBRE program of the National Center for Research Resources, NIH (grant number P20RR016741).

Acknowledgements

The authors acknowledge Dr Katherine I O’Rourke, USDA-ARS, Pullman, WA, for funding and leadership in the PrPc studies at North Dakota State University. They also acknowledge Dr Jerzy Bilski, Dr Pawel Borowicz, Ms Tammi Neville, Mr James D Kirsch, Mr Kim C Kraft, Mr Robert Weigl, Mr Terry Skunberg, and other members of our laboratory and department for their assistance and the efforts of several of our graduate and undergraduate students in this research project: Roza Yunosova, Mahalakshmi Razdan, Anirudh Gautam, and Mathilde Rupin.

References


